GoodRx Announces Agreement with Surescripts to Provide Real-Time Drug Discount Pricing in Electronic Health Records
August 05 2021 - 9:00AM
GoodRx (NASDAQ: GDRX), America’s leading resource for healthcare
savings, today announced that it has entered into an agreement with
Surescripts, the nation’s leading health information network, to
deliver drug discount price information to prescribers using
Surescripts Real-Time Prescription Benefit when prescribing
medications for uninsured patients and patients whose price
information isn’t already available from their PBM or health plan.
Surescripts Real-Time Prescription Benefit delivers cost
information in the electronic workflow so prescribers can make more
informed decisions and address patient prescription cost concerns
at the point of care.
Approximately one-third of Americans say they have skipped
filling a prescription for a chronic condition one or more times
because of the cost, according to an internal GoodRx survey. By
improving price transparency at the point of care, prescribers can
have more informed conversations with their patients and ensure
they can afford the treatment they need before getting to the
pharmacy counter. With this new integration, prescribers using
Surescripts Real-Time Prescription Benefit will be able to provide
uninsured patients and patients whose price information isn’t
already available from their PBM or health plan with drug discount
pricing from GoodRx, which provides savings of up to 80% from
pharmacy retail prices on prescriptions, so patients can make more
educated decisions about their care.
“We are always looking for ways to increase prescription price
transparency and affordability for more Americans, so we are
excited to work with Surescripts to arm prescribers with the tools
and information they need to choose medications that are both
accessible and clinically appropriate,” said Doug Hirsch, co-CEO
and co-founder of GoodRx.
Surescripts is a nationwide network that connects virtually all
electronic health records software vendors (EHRs), pharmacies and
health systems, enabling providers to view patient-specific benefit
and cost information and then electronically prescribe a
medication. Last year, nearly 2 billion electronic prescriptions
were delivered through Surescripts. Integrating GoodRx pricing will
support getting cost information into the hands of patients.
“Providing prescription price transparency at the point of care
is critical to improving medication adherence and ensuring patients
can receive the treatment they need,” said Mike Pritts, Chief
Product Officer, at Surescripts. “With the addition of our drug
discount pricing feature for uninsured patients as well as patients
whose price information isn’t already available from their PBM or
health plan, Real-Time Prescription Benefit arms prescribers with
more of the information they need, so they can have meaningful cost
conversations and get patients started on medication they can
access and afford.”
To learn more about GoodRx, visit goodrx.com.
About GoodRxGoodRx helps Americans get the
healthcare they need at a price they can afford. As America’s
leading resource for healthcare savings, GoodRx connects consumers
with affordable and convenient prescriptions and medical care,
including telehealth, mail order prescriptions, doctor visits, and
lab tests. We have helped Americans save over $30 billion since
2011 and are one of the most downloaded medical apps over the past
decade.
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation statements regarding consumer savings, the
availability and use of GoodRx pricing in the Surescripts product
and benefits and use of GoodRx pricing by Surescripts providers and
patients. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, risks
relating to our acquisition strategy, the integration of acquired
business and the important factors discussed under the caption
“Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year
ended December 31, 2020, and our other filings with the SEC. These
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
ContactGoodRxLauren
Casparispress@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024